SCHEMBL20048870

SCHEMBL20048870

CCCC(C)(C)c1c[nH]c2ncccc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 1/20 0.49
AXL P30530 1/20 0.46
MET P08581 2/20 0.43
LRRK2 Q5S007 1/20 0.43
KMT2A Q03164 1/20 0.43
PDPK1 O15530 5/20 0.42
MAP2K1 Q02750 1/20 0.42
JAK3 P52333 1/20 0.41
MTNR1A P48039 1/20 0.41
CDC7 O00311 1/20 0.41
ROCK2 O75116 1/20 0.41
MAP4K4 O95819 1/20 0.41
PIM1 P11309 1/20 0.41
PRKACA P17612 1/20 0.41
CDK2 P24941 1/20 0.41
GSK3B P49841 1/20 0.41
HIPK2 Q9H2X6 1/20 0.41
CLK4 Q9HAZ1 1/20 0.41
MKNK2 Q9HBH9 1/20 0.41
IRAK4 Q9NWZ3 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19788274 0.88 GPR84 (0.51) GPR84AXLMETLRRK2KMT2A
SCHEMBL20110128 0.83 GPR84 (0.50) GPR84AXLMETLRRK2KMT2A
SCHEMBL20111711 0.82 GPR84 (0.46) GPR84AXLMETLRRK2KMT2A
SCHEMBL18103493 0.82 GPR84 (0.53) GPR84AXLMETLRRK2KMT2A
SCHEMBL762568 0.80 AXL (0.55) GPR84AXLMETLRRK2KMT2A
SCHEMBL19286544 0.78 PRKCI (0.46) AXLLRRK2MAP2K1JAK3ROCK2
SCHEMBL18462239 0.77 GPR84 (0.39) GPR84AXLMETLRRK2KMT2A
SCHEMBL21151891 0.76 MAPK1 (0.42) LRRK2PDPK1CDC7MAP4K4CDK2
SCHEMBL24001454 0.76 LATS1 (0.38) LATS1
SCHEMBL27764323 0.75 AXL (0.49) GPR84AXLMETLRRK2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10421761-B2 Compounds for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2019-09-24 US disclosed
US-20180099975-A1 COMPOUNDS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2018-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10421761-B2 Compounds for kinase modulation, and indications therefor MAP3K20, MAP3K13, MAP3K8 GPR84 3756/4885AXL 1495/4885MET 497/4885
US-20180099975-A1 COMPOUNDS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, MAP3K13, MAP3K8 GPR84 3756/4885AXL 1495/4885MET 497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.